(Q35588682)

English

HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques

scientific article published on July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

0 references

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

author name string

C M Ellis

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M J Dyson

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

T J Stephenson

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

E L Maltby

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Journal of Clinical Pathology

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

710-714

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Testing for HER2 in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

12 July 2018

Best Practice No 176: Updated recommendations for HER2 testing in the UK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

12 July 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

12 July 2018

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

12 July 2018

Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

12 July 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

12 July 2018

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

26 September 2018

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

26 September 2018

Evaluating HER2 amplification and overexpression in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

26 September 2018

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770709

26 September 2018

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://pubmed.ncbi.nlm.nih.gov/15976337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15976337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15976337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/JCP.2004.023424

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35588682&oldid=2165605331"